Treatment for Acute Myeloid Leukemia: IDHIFA (Enasidenib)

 

In the world of oncology, breakthroughs in targeted therapies have opened new avenues for the treatment of various types of cancer. One such remarkable advancement is the introduction of IDHIFA (Enasidenib), a medication that has shown great promise in the fight against acute myeloidleukemia (AML).

Understanding IDHIFA and AML:

 IDHIFA, known by its generic name Enasidenib, is an oral medication that targets a specific mutation known as isocitrate dehydrogenase 2 (IDH2). Mutations in the IDH2 gene are found in approximately 12-20% of AML patients. These mutations lead to the production of an abnormal form of the IDH2 enzyme, which plays a significant role in the development and progression of AML.

Approved Indication: IDHIFA is specifically indicated for the treatment of adult patients with relapsed or refractory AML harboring an IDH2 mutation. It is not intended for use in patients with other types of leukemia or those without the IDH2 mutation.

Accessing IDHIFA: Obtaining IDHIFA requires a prescription from a qualified healthcare professional, typically an oncologist or hematologist. If you or a loved one has been diagnosed with relapsed or refractory AML and have the IDH2 mutation, your healthcare provider will evaluate your eligibility for IDHIFA treatment based on various factors, including medical history and genetic testing results.

To acquire IDHIFA, you will need to follow these steps:

Consultation with a Healthcare Provider: Schedule an appointment with an oncologist or hematologist who specializes in AML treatment. Discuss your medical history, symptoms, and previous treatments.

Genetic Testing: Your healthcare provider will order genetic testing to determine if you have the IDH2 mutation. This will involve a sample collection, typically through a blood test or bone marrow biopsy.

Evaluation of Treatment Options: If the genetic testing confirms the presence of the IDH2 mutation and you meet the necessary criteria, your healthcare provider may discuss IDHIFA as a potential treatment option. They will consider other factors such as your overall health, treatment history, and individualized treatment plan.

Prescription and Access: If IDHIFA is deemed suitable for your condition, your healthcare provider will write a prescription for the medication. You can then obtain the prescription from a local pharmacy or explore specialized pharmacies that deal with oncology medications. It is important to check with your insurance provider regarding coverage and any potential financial assistance programs that may be available.

How and Where to Buy IDHIFA (Enasidenib)

To get the accurate and latest pricing information, it is crucial to know the treatment recommendations in the context of the dosage and quantity of medicines. Legally importing products like IDHIFA (Enasidenib) tablets is recommended in order to make sure genuineness of the medicine.

It may seem tough for patients if they want to source or buy IDHIFA (Enasidenib) from India, which is not registered in India. If all the needed documents are available, then it is very easy to secure an import permit from CDSCO. To buy IDHIFA (Enasidenib) legally, Patients, Hospitals, and Health Specialists can confidently engage with a licensed service provider AlleviareIndia.  We can help facilitate the supply of IDHIFA (Enasidenib) 100 Mg Tablets inIndia and other countries across the world.


Comments

Post a Comment

Popular posts from this blog

What Patients Should Know about Early Access Programs- AlleviareIndia

Image
  Introduction: In the world of medical research and development, new treatments, drugs, and therapies are constantly being developed to address various health conditions. However, the journey from initial development to final approval by regulatory authorities can be a lengthy process, leaving many patients eagerly awaiting access to potentially life-saving treatments. This is where Early Access Programs (EAPs) come into play. In this article, we will explore what patients should consider when participating in an Early Access Program. Understand the Purpose and Eligibility Criteria: Before considering participation in an Early Access Program, it's important to understand its purpose. EAPs are designed to provide access to investigational treatments for patients who have exhausted all other available options and have a serious or life-threatening condition. Familiarize yourself with the eligibility criteria to determine if you meet the necessary requirements. Discuss with
Read more

Abatacept (Orencia)

Image
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy. Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion. It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied. Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communicatio
Read more